Axogen Inc (AXGN) Peer Comparison

$51.23

$-0.50 (-0.97%)

As on 28-Aug-2026 13:33EDT

Market cap

$2,710 Mln

Revenue (TTM)

$251 Mln

P/E Ratio

--

P/B Ratio

9.7

Div. Yield

0 %

Edit

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	2,710	12,753	10,906	10,222	9,762
Revenue ($ Mln)	251	1,505	613	785	2,589
Net Profit ($ Mln)	-33.55	160.59	-188.05	41.54	222.40
Net Margin (%)	-13.36	10.67	-30.68	5.29	8.59
RoE (%)	-17.42	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	9.75	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	251.17	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	63.91	483.98	127.96	384.30	1,245.50
Gross Profit	167.35	942.44	393.22	347.62	1,343.60
Operating Expenses	200.11	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-12.85	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-33.55	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-33.55	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	256.26	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	18.23	210.18	135.71	705.49	2,116.80
Current Liabilities	30.37	233.78	102.33	132.66	961.30
Total Liabilities	221.69	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	104.49	630.60	404.74	1,749.63	7,231.50
Current Assets	200.38	1,344.12	515.78	1,200.55	3,020.50
Total Assets	221.69	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	20.07	212.71	102.84	690.94	1,203.70
Net Current Assets	170.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	0.81	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-5.32	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	10.50	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-8.51	11.76	-22.53	1.79	8.98
ROE (%)	-17.42	10.86	-28.10	1.97	3.04
ROA (%)	-11.86	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-7.73	13.63	-30.58	9.87	-5.99
Net Margin (%)	-13.36	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	23.57	17.55	41.55	16.49	1.37
EBIT Growth (%)	-695.92	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-619.45	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-540.28	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	95.15	17.33	-12.65	2.16	2.19

Valuation Ratios

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-97.82	68.93	-34.59	189.42	--
Price / Book Value	11.92	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	8,135.92	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.01	0.01	0.00	0.01	0.06
Current Ratio	6.60	5.75	5.04	9.05	3.14
Quick Ratio	5.04	3.86	4.46	7.64	2.33
Interest Coverage	-1.66	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Axogen Inc (AXGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	13.59	12.65	22.67	20.09	17.06
Asset Turnover	0.89	0.74	0.59	0.26	0.24
Receivable days	40.77	46.54	60.95	72.41	65.39
Inventory Days	238.50	331.92	193.84	146.53	221.09
Payable days	34.39	26.16	60.19	29.05	37.02
Cash Conversion Cycle	244.87	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly